Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

(2013) John P.H. Wilding   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan

(2013) Yehuda Handelsman et al.   Endocrine Practice

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

(2012) J. Rosenstock et al.   DIABETES CARE

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

(2012) R. R. Henry et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Learning From Glycosuria: FIG. 1.

(2011) Ele Ferrannini   DIABETES

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Effect of kidney disease on glucose handling (including genetic defects)

(2011) Joaquim Calado et al.   KIDNEY INTERNATIONAL

Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor

(2011) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule

(2010) V. Vallon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Sodium-glucose transporter-2 inhibition as an antidiabetic therapy

(2010) E. Ferrannini   NEPHROLOGY DIALYSIS TRANSPLANTATION

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

(2010) Jian Chen et al.   Diabetes Therapy

Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006

(2009) Bernard M.Y. Cheung et al.   AMERICAN JOURNAL OF MEDICINE

Defining and Characterizing the Progression of Type 2 Diabetes

(2009) V. A. Fonseca   DIABETES CARE

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Hypoglycaemia in Type 2 diabetes

(2008) S. A. Amiel et al.   DIABETIC MEDICINE

Why Don’t Diabetes Patients Achieve Recommended Risk Factor Targets? Poor Adherence versus Lack of Treatment Intensification

(2008) Julie A. Schmittdiel et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE